OcuTerra completed a $35 million Series B financing in November 2021 to support the conduct of a Phase 2 clinical trial of OTT166 in patients with diabetic retinopathy.

This Phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) trial is currently underway and is forecasted to be completed by early 2024. The company also plans to evaluate OTT166 in other retinal indications.

Investor contact: IR@ocuterratx.com